A review published in Obstetrics & Gynecology evaluated the efficacy and safety of elinzanetant and fezolinetant for managing vasomotor symptoms (VMS).
In this systematic review and meta-analysis, including seven randomized controlled trials with 4,087 menopausal women, both drugs were associated with reductions in the frequency and severity of VMS symptoms. Elinzanetant 120 mg also showed improvement in sleep quality, with reported adverse events including drug-related events and headache.
Overall, the findings suggest that both fezolinetant and elinzanetant provide beneficial outcomes for managing menopausal vasomotor symptoms, with elinzanetant showing a larger effect on symptom reduction and sleep improvement.
Reference:
De Almeida AM, Oliveira P, Lopes L, Leite M, Morbach V, Kelly FA, Barros Í, de Moraes FC, Prevedello A. Fezolinetant and elinzanetant therapy for menopausal women experiencing vasomotor symptoms: a systematic review and meta-analysis. Obstetrics & Gynecology. 2022 May 5:10-97.
https://journals.lww.com/greenjournal/fulltext/2025/03000/fezolinetant_and_elinzanetant_therapy_for.3.aspx
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
Please login to comment on this article